Trends in biotechnology· 2026Q1
The FDA’s plan to phase out animal testing
- 28citations
- Q1SCImago
- 2026year
Short summary
The FDA is developing a roadmap to phase out animal testing for drug development, guided by the FDA Modernization Act 2.0 and 3.0, aiming for cheaper, safer drugs without animal suffering.
AI-generated from the title and abstract; the full text is not read.
Key points
- The FDA is creating a roadmap to phase out animal testing.
- This initiative is driven by the FDA Modernization Act 2.0 and 3.0.
- New Approach Methodologies (NAMs) are central to this transition.
- The goal is to develop cheaper and safer drugs with reduced animal suffering.
AI-generated from the title and abstract; the full text is not read.
Abstract
Replacing animal testing through 'New Approach Methodologies' holds promise for developing cheaper and safer drugs without animal suffering. However, such an approach should be implemented carefully, and it cannot be rushed. We discuss the FDA Modernization Act 2.0 and 3.0 and the FDA's roadmap to phase out animal testing.
The authors' abstract, as published at the source. Trends in biotechnology, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Small AnimalsVeterinary